Pfizer Zyrtec comparative onset of action claims "appear to be substantiated" -- FDA ad letter.
Executive Summary
PFIZER ZYRTEC ONSET OF ACTION COMPARISONS "APPEAR TO BE SUBSTANTIATED," FDA told the company in an April 28 letter from the Division of Drug Marketing, Advertising & Communications. The letter cites a pair of two-day trials comparing the Pfizer product to Schering-Plough's Claritin in terms of onset of antihistamine activity: a Journal of Allergy and Clinical Immunology study by Meltzer et al. and an unpublished study from a controlled environmental exposure unit.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth